Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 32101564 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | NA | NA | negation | |
| we compared health care utilization (inpatient hospital days, emergency care visits) and health care-related costs between scd adults that underwent hematopoietic stem cell transplantation (hsct) using a nonmyeloblative conditioning regimen versus those referred for hsct but did not proceed due to lack of an hla-matched sibling donor, denial by insurance, red blood cell antibodies to the potential donor, or declining further evaluation. | |||||||
| 32112480 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hematopoietic stem cell transplantation | NA | NA | NA | negation | |
| donor-specific anti-human leukocyte antigen (hla) antibodies (dsas) in recipients is a risk factor for donor stem cell graft failure in haploidentical hematopoietic stem cell transplantation (haplo-hsct), and the treatment to reduce the levels of dsas is not unanimous. | |||||||
| 32112480 | HLA (HLA) | haploidentical transplantation | NA | NA | NA | unclassified | |
| combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-hla antibodies for stem cells engraftment in haploidentical transplantation. | |||||||
| 32133364 | HLA (HLA) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| in the setting of hematopoietic stem cell transplantation, donor-patient hla matching is the prime donor selection criterion. | |||||||
| 32143579 | HLA IDENTICAL (HLA-IDENTICAL) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| cd19 car-t therapy followed by hla-identical unrelated hematopoietic stem cell transplantation was applied and the patient remains in remission for 7 months till now. | |||||||
| 32170765 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| human leukocyte antigen (hla)-haploidentical hematopoietic stem cell transplantation (haplo-hsct) is an effective alternative to hla-matched transplantation. | |||||||
| 32170853 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | Japanese | NA | NA | negation | |
| although outcomes of hematopoietic stem cell transplantation from alternative donors have been improved, it has not yet challenged the precedence of hla-matched or a few loci-mismatched donors. | |||||||
| 32205853 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | cyclophosphamide | NA | positive | |
| cytomegalovirus (cmv) dnaemia and cmv disease have been reported as more frequent in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (haplo-hsct) than in those receiving hla-matched allografts. | |||||||
| 32367074 | HLA (HLA) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| correction: high-resolution hla phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. | |||||||
| 32387075 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | Canadian | NA | NA | unclassified | |
| / patients in need of hematopoietic stem cell transplantation often cannot find a suitable hla-matched donor in their families and rely on unrelated donors. | |||||||
Copyright 2024